Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Phillip Monk, Richard Marsden, Victoria Tear, et al.
The Lancet Respiratory Medicine (2020) Vol. 9, Iss. 2, pp. 196-206
Open Access | Times Cited: 428

Showing 76-100 of 428 citing articles:

Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 561-585
Open Access | Times Cited: 32
Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review
Claudio Tirelli, Mara De Amici, Cristina Albrici, et al.
Biology (2023) Vol. 12, Iss. 2, pp. 177-177
Open Access | Times Cited: 29
Antiviral Therapy of COVID-19
Georgii Gudima, И.А. Кофиади, I.P. Shilovskiy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8867-8867
Open Access | Times Cited: 24
After the Hurricane: Anti-COVID-19 Drugs Development, Molecular Mechanisms of Action and Future Perspectives
Hazim O. Khalifa, Yousef Al Ramahi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 739-739
Open Access | Times Cited: 12
Investigational pharmacological agents for the treatment of ARDS
Katyayini Aribindi, Michelle Lim, Satyan Lakshminrusimha, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 3, pp. 243-277
Closed Access | Times Cited: 9
Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19
R. K. Subbarao Malireddi, Bhesh Raj Sharma, Thirumala‐Devi Kanneganti
Annual Review of Immunology (2024) Vol. 42, Iss. 1, pp. 615-645
Closed Access | Times Cited: 8
Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm
Zhen Wang, Lei Xiang, Feng Lin, et al.
Matter (2021) Vol. 5, Iss. 1, pp. 336-362
Open Access | Times Cited: 53
Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model
Pierre Bessière, Marine Wasniewski, Evelyne Picard‐Meyer, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 8, pp. e1009427-e1009427
Open Access | Times Cited: 52
Interferon Resistance of Emerging SARS-CoV-2 Variants
Kejun Guo, Bradley S. Barrett, Kaylee L. Mickens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 50
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
Marcello Allegretti, Maria Candida Cesta, Mara Zippoli, et al.
Cell Death and Differentiation (2021) Vol. 29, Iss. 1, pp. 156-166
Open Access | Times Cited: 50
Current evidence for COVID-19 therapies: a systematic literature review
Tobias Welte, Lucy Ambrose, Gillian C. Sibbring, et al.
European Respiratory Review (2021) Vol. 30, Iss. 159, pp. 200384-200384
Open Access | Times Cited: 46
Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
Paul Bastard, Romain Lévy, Soledad Henriquez, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 5, pp. 931-933
Open Access | Times Cited: 45
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19
Carolina García‐Vidal, Rodrigo Alonso, Ana M. Camon, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 12, pp. 3296-3302
Open Access | Times Cited: 44
Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis
Rafaela Pires da Silva, João Ismael Budelon Gonçalves, Rafael Fernandes Zanin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 43
Type I Interferons in COVID-19 Pathogenesis
Enrico Palermo, Daniele Di Carlo, Marco Sgarbanti, et al.
Biology (2021) Vol. 10, Iss. 9, pp. 829-829
Open Access | Times Cited: 43
The role of antirheumatics in patients with COVID-19
Christoffer B Nissen, Savino Sciascia, Danieli Andrade, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 6, pp. e447-e459
Open Access | Times Cited: 42
Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system
Qingyuan Zhu, Yaling Zhang, Li Wang, et al.
Antiviral Research (2021) Vol. 187, pp. 105015-105015
Open Access | Times Cited: 40
Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Carly G.K. Ziegler, Vincent N. Miao, Anna H. Owings, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 40
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Donald C. Vinh, Laurent Abel, Paul Bastard, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 7, pp. 1425-1442
Open Access | Times Cited: 40
ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
Daniel J. Rawle, Thuy T. Le, Troy Dumenil, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 7, pp. e1009723-e1009723
Open Access | Times Cited: 40
SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
Denisa Bojková, Tamara Rothenburger, Sandra Ciesek, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 35
Interferon Treatments for SARS-CoV-2: Challenges and Opportunities
Diya Jhuti, Angeli Rawat, Christina M. Guo, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 3, pp. 953-972
Open Access | Times Cited: 28
Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease
Charles E. Samuel
Journal of Biological Chemistry (2023) Vol. 299, Iss. 8, pp. 104960-104960
Open Access | Times Cited: 20
Treatment of COVID‐19 patients with a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation
Musa Khaitov, Alexandra Nikonova, И.А. Кофиади, et al.
Allergy (2023) Vol. 78, Iss. 6, pp. 1639-1653
Open Access | Times Cited: 18
Clinical efficacy and safety of interferon (Type I and Type III) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
Seungeun Ryoo, Dae-Hyup Koh, Su‐Yeon Yu, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0272826-e0272826
Open Access | Times Cited: 17

Scroll to top